Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD)

Fig. 2

NSCLC with COPD showed a down-regulation of HHLA2. (A) Left: Volcanic map of differential genes in 40 samples paired with NSCLC with COPD and NSCLC without COPD. Right: Volcanic map of differential genes in 175 TCGA samples paired with NSCLC with COPD and NSCLC without COPD. The blue and orange dots represent down-regulated and up-regulated genes, respectively. (B) Venn diagram of the intersection of differential genes mentioned above. (C) Representative image of HHLA2 immunohistochemical staining. Left: NSCLC with COPD; Right: NSCLC without COPD. (D) Statistical chart of HHLA2 immunohistochemical staining in NSCLC with COPD versus NSCLC without COPD. (E) Representative images of HHLA2 immunohistochemical staining. Left: the MPR group; Right: the non-MPR group. (F) Statistical chart of HHLA2 immunohistochemical staining in the MPR group versus the non-MPR group. Scale bars, 100 μm. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us